GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms

Biochimica Et Biophysica Acta. Molecular Basis of Disease
Manfredi RizzoFrancesco Cosentino

Abstract

Type 2 diabetes mellitus (T2DM) is a metabolic condition with an elevated impact on cardiovascular (CV) risk. The innovative therapeutic approaches for T2DM - incretin-based therapies (IBTs), including glucagon-like peptide 1 (GLP-1) receptor agonists, have become popular and more widely used in recent years. The available scientific data from clinical studies and clinical practice highlights their beyond glucose-lowering effects, which is achieved without any increase in hypoglycaemia. The former effects include reduction in body weight, lipids, blood pressure, inflammatory markers, oxidative stress, endothelial dysfunction, and subclinical atherosclerosis, thus reducing and potentially preventing CV events. In fact, the introduction of IBTs is one of the key moments in the history of diabetes research and treatment. Such therapeutic strategies allow customization of antidiabetic treatment to each patient's need and therefore obtain better metabolic control with reduced CV risk. The aim of the present paper is to provide a comprehensive overview of the effects of GLP-1RA on various cardiometabolic markers and overall CV risk, with particular attention on recent CV outcome studies and potential mechanisms. In particular, the ef...Continue Reading

Citations

Jan 16, 2019·Expert Review of Clinical Pharmacology·Angelo Maria PattiAli A Rizvi
Sep 1, 2019·Current Pharmaceutical Design·Alessandra VecchiéAldo Bonaventura
Apr 1, 2020·Journal of Clinical Medicine·Angelo Maria PattiFerdinando Mannello
Jul 4, 2020·Journal of Cardiovascular Pharmacology and Therapeutics·Anca Pantea StoianManfredi Rizzo
May 16, 2020·Diabetes Care·Antonio CerielloUNKNOWN Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group
Jun 26, 2020·Metabolic Syndrome and Related Disorders·Rona ZhouArthur Swislocki
Jul 28, 2020·Journal of Clinical Medicine·Chrysi KoliakiNikolaos Tentolouris
Jul 13, 2019·Current Pharmaceutical Design·Adriana Florinela CӑtoiManfredi Rizzo
Apr 27, 2021·Current Opinion in Lipidology·Amanda J Berberich, Robert A Hegele
May 1, 2021·International Journal of Molecular Sciences·Rosaria Vincenza GiglioManfredi Rizzo
Jul 5, 2021·Diabetes Research and Clinical Practice·Sanjib SarkarPrasenjit Manna
Aug 24, 2021·Expert Opinion on Drug Safety·Yajnavalka BanerjeeManfredi Rizzo
Sep 19, 2021·Scientific Reports·Emilie H ZobelJoachim Størling
Oct 2, 2021·Expert Opinion on Drug Safety·Yajnavalka BanerjeeManfredi Rizzo
Oct 27, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Djordje S PopovicManfredi Rizzo
Dec 31, 2021·Metabolic Syndrome and Related Disorders·Anca Pantea StoianManfredi Rizzo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Diabetes

This feed focuses on the latest research on biomarkers used for monitoring disease progression in diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Related Papers

Giornale italiano di cardiologia : organo ufficiale della Federazione italiana di cardiologia : organo ufficiale della Società italiana di chirurgia cardiaca
Rosaria Vincenza GiglioManfredi Rizzo
Expert Review of Cardiovascular Therapy
Carolyn F Deacon, Nikolaus Marx
World Journal of Pediatrics : WJP
Bao-Sheng Yu, An-Ru Wang
© 2022 Meta ULC. All rights reserved